Form 4: Kodiak Sciences Director Granted 40,000 Stock Options

Kodiak Sciences Inc. Director Bassil I. Dahiyat was granted 40,000 stock options with an exercise price of $3.73, vesting upon continued service.

Summary

• Director Bassil I. Dahiyat of Kodiak Sciences Inc. was granted 40,000 stock options.
• The options have an exercise price of $3.73 per share.
• The grant date for these options was June 30, 2025.
• The options will vest 100% upon the earlier of June 30, 2026, or one day prior to the Issuer's next annual meeting occurring after the grant date.
• Vesting is contingent on the reporting person continuing to serve as a member of the Issuer's board of directors through the applicable vesting date.
• The options expire on June 29, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal for aligning management incentives with shareholder interests and is a standard compensation practice.

Positives

• The grant of 40,000 stock options to a director aligns management incentives with shareholder interests.
• The options have a long expiration date of June 29, 2035, providing a long-term incentive for the director.

Future Outlook

The vesting schedule for the granted options indicates an expectation for Director Bassil I. Dahiyat to continue serving on the board until at least June 30, 2026, or the next annual meeting.

Industry Context

This Form 4 filing represents a routine insider transaction, common in the biotechnology and pharmaceutical sectors, where equity grants are frequently used to incentivize and retain key directors and executives, aligning their interests with long-term company performance.

Comparison to Industry Standards

• Equity grants to directors, such as the 40,000 stock options granted to Bassil I. Dahiyat, are a standard practice across the biotechnology and pharmaceutical industries.
• Companies like Regeneron Pharmaceuticals (REGN) and Biogen (BIIB) frequently utilize similar long-term incentive plans to compensate and retain board members and executives, often tying vesting to continued service and company performance milestones.
• The exercise price of $3.73 reflects the stock price at the time of grant, a common approach for incentive options.

Related Party Transactions

• Grant of 40,000 stock options to Bassil I. Dahiyat, a director of Kodiak Sciences Inc., with an exercise price of $3.73.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their financial interests with the long-term performance of the company, potentially benefiting shareholders if the stock price increases.

Next Steps

• Director Bassil I. Dahiyat's continued service on the board of directors is required for the options to vest.
• The options will become fully vested upon the earlier of June 30, 2026, or one day prior to the Issuer's next annual meeting after the grant date.

Key Dates

Keywords

Kodiak Sciences, KOD, Stock Option, Director, Insider Transaction, Form 4, Equity Grant, Vesting